India's Aurobindo Pharma down after US FDA flags serious concerns at facility
15/06/2026 06:23
BUZZ-India's Aurobindo Pharma down after US FDA flags serious concerns at facility ** Shares of India's Aurobindo Pharma ARBN.NS down 1.3% to 1,453.8 rupees, snapping a three-session winning streak
** Stock set for biggest percentage fall since May 27, if losses hold
** US FDA on Friday flagged inspection classification of subsidiary's facility in Telangana as "official action indicated" - most serious FDA inspection classification
** Regulator concluded the inspection with 11 observations, co said
** ARBN noted it is committed to maintaining quality manufacturing standards across all facilities
** YTD, stock up 12.47%
(Reporting by Saikeerthi in Bengaluru)
((Saikeerthi@thomsonreuters.com; (+91) 8296756080))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma USA Receives FTC Approval To Acquire Lannett Company
Brief: Aurobindo Pharma Obtains US FTC Approval For Lannett Acquisition
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett (updated)
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc.
HSBC sees no earnings hit from FDA action on India's Aurobindo Pharma